NESCO, Cineline Gain in Q1 FY27; Epigral Profit Dips

Indian firms have presented a mixed earnings landscape for the June 2026 quarter, marking the first quarter of FY27. NESCO and Cineline India demonstrated robust performances, with NESCO reporting increased profits and Cineline India significantly narrowing its net loss. Conversely, Epigral faced a notable decline in net profit despite recording revenue growth.

NESCO Posts Strong Profit and Revenue Growth

NESCO reported a substantial increase in profit after tax for the June 2026 quarter, building on its previous year’s performance. The company also registered a significant uplift in its quarterly revenue, underscoring strong operational efficiency.

• Profit After Tax: Rs 999.60 million, up from Rs 962.00 million.
• Revenue: Rs 2118.00 million, a 9.55% increase.
• Operating Profit: Rs 1459.70 million.

Cineline India Narrows Losses on Robust Sales

Cineline India experienced a considerable surge in sales during the June 2026 quarter, contributing to a substantial reduction in its net losses. This performance indicates a positive trajectory for the company compared to the prior year.

• Sales: Rs 592.75 million, an increase of 30.88% from Rs 452.90 million.
• Net Loss: Reduced to Rs -12.11 million from Rs -20.58 million.
• Operating Profit: Rs 126.14 million.

Epigral Registers Profit Decline Despite Revenue Rise

Epigral recorded a significant fall in net profit for the June 2026 quarter, even as the company’s revenue expanded. The decline in profitability contrasts with its growth in operating profit over the same period.

• Net Profit Fall: -38.17%.
• Revenue: Rs 7053.60 million, growing 16.29% from Rs 6065.40 million.
• Operating Profit: Rs 1833.00 million, an increase from Rs 1716.40 million.

The varied financial outcomes across these key Indian firms highlight the dynamic nature of the market as companies navigate the current economic landscape in the first quarter of the fiscal year.